FDA Approves Rybrevant
FDA Approves Rybrevant (amivantamab-vmjw) as the First Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20
Read moreFDA Approves Rybrevant (amivantamab-vmjw) as the First Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20
Read moreThe first doses of the COVID-19 vaccine were administered back in December 2020, according to The Washington Post, but that
Read more(HealthDay)—The U.S. Food and Drug Administration approved use of a higher dose of naloxone hydrochloride nasal spray for treating opioid
Read moreThe US Food and Drug Administration (FDA) announced today that it plans on taking steps within the next year to ban
Read moreThe Biden administration has taken the first step toward ending an emergency exception that allowed hospitals to ration and reuse
Read moreFOSTER CITY, Calif.–(BUSINESS WIRE)–Apr. 13, 2021– Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration
Read moreEditor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center. Dozens of Americans are rolling up
Read moreThe US Food and Drug Administration has declared Medtronic’s recall of seven models of defibrillating cardiac rhythm devices, due to
Read morePARIS, March 31, 2021 /PRNewswire/ — The U.S. Food and Drug Administration (FDA) has approved Sarclisa (isatuximab-irfc) in combination with
Read moreThe US Food and Drug Administration (FDA) has expanded the indication for Mirabegron (Myrbetriq/Myrbetriq Granules) to treat neurogenic detrusor overactivity
Read more